التفاصيل البيبلوغرافية
| العنوان: |
Evaluating the Use of Glucagon-Like Peptide 1 Receptor Agonists (GLP1 RA) in a Matched Cohort of Kidney and Liver Transplant Recipients |
| المؤلفون: |
Baik, Isabel, Gonzalez, Humberto C, Jantz, Arin, Poparad-Stezar, Adina, Summers, Bryant, Venkat, Deepak, Samaniego-Picota, Milagros D, Fitzmaurice, Mary G |
| المصدر: |
Gastroenterology Meeting Abstracts |
| بيانات النشر: |
Henry Ford Health Scholarly Commons |
| سنة النشر: |
2023 |
| المجموعة: |
Henry Ford Health System Scholarly Commons |
| مصطلحات موضوعية: |
glucagon like peptide 1 receptor agonist, hemoglobin A1c, insulin, abdominal pain, acute graft rejection, adult, adverse drug reaction, body mass, body weight, cohort analysis, complication, conference abstract, controlled study, diabetes mellitus, drug safety, drug therapy, drug withdrawal, female, graft failure, human, incidence, kidney graft, liver graft, major clinical study, male, mortality, retrospective study, side effect, summer, surgery |
| الوصف: |
Purpose: To assess the safety and efficacy of GLP1 RA in a matched cohort of kidney transplant (KT) and liver transplant (LT) recipients who received these agents compared to patients who did not Methods: This single-center, retrospective analysis evaluated KT and LT recipients who were initiated on a GLP1 RA for at least 3 months (mo) matched to a nonintervention comparator group (non-GLP1 RA) based on organ type and diagnosis of diabetes mellitus present at time of transplant. The primary endpoint was change in hemoglobin A1C (HbA1c) at 6 mo. Secondary endpoints included weight (kg), BMI (kg/m2), insulin requirements, and number of oral diabetic agents (ODAs). Safety outcomes included incidence of adverse events (AEs), biopsy-proven acute rejection (BPAR), graft loss, and mortality. Results: Of the 74 patients included, 37 received GLP1 RA matched to 37 patients who did not. Baseline characteristics shown in Table 1. More patients in the GLP1 RA group were on ODAs and 10 patients (27%) initiated on an agent <1 year from transplant. Change in median HbA1c in GLP1 RA group from baseline to 6 mo was -0.5% [(7.0% (6.4-8.9); 6.5% (5.6-7.3)] compared to +0.6% in the non-GLP1 RA group [(5.8% (5.5-6.8); 6.6% (5.8-7.6)], p=0.53. Median change in total daily insulin units was -13 units vs +15 units in the GLP1 RA vs non-GLP1 RA group (p=0.16). GLP1 RA group median change in weight was -7.4 kg vs -0.3 kg in non-GLP1 RA group (p=0.02). BMI change was -3.1 kg/m2 in GLP1 RA vs +0.7 kg/m2 in non-GLP1 RA, p=0.02. In GLP1 RA group, 7 patients (38.9%) experienced an AEs related to drug with 4 (10.8%) leading to discontinuation. Common AE being abdominal pain. One patient (2.7%) discontinued drug due to cost, 3 patients (8.1%) found it ineffective, and 1 (2.7%) had a drug-unrelated discontinuation. Eight patients (21.6%) in each group experienced BPAR. In the GLP1 RA group, 1 patient had graft loss compared to 2 patients in the non-GLP1 RA. No patient deaths occurred with GLP1 RA while 2 patient deaths in the comparator ... |
| نوع الوثيقة: |
text |
| اللغة: |
unknown |
| العلاقة: |
https://scholarlycommons.henryford.com/gastroenterology_mtgabstracts/200Test; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=16006143&id=doi:10.1016%2Fj.ajt.2023.05.014&atitle=Evaluating+the+Use+of+Glucagon-Like+Peptide+1+Receptor+Agonists+%28GLP1+RA%29+in+a+Matched+Cohort+of+Kidney+and+Liver+Transplant+Recipients&stitle=Am.+J.+Transplant.&title=American+Journal+of+Transplantation&volume=23&issue=6&spage=S947&epage=&aulast=Baik&aufirst=I.&auinit=I.&aufull=Baik+I.&coden=&isbn=&pages=S947-&date=2023&auinit1=I&auinitmTest= |
| الإتاحة: |
https://scholarlycommons.henryford.com/gastroenterology_mtgabstracts/200Test |
| رقم الانضمام: |
edsbas.EB9513BF |
| قاعدة البيانات: |
BASE |
